Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025
Article content
BAAR, Switzerland — Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow (United Kingdom) June 13-16.
Article content
The company will present 25 posters and host two scientific symposia during which six world-leading experts will share their insight on respiratory and food allergy:
Article content
'Breath of change: redefining respiratory allergy care with remission in sight': with environmental change impacting respiratory allergies, a new approach to disease management is necessary. Clinical remission is emerging as a relevant treatment goal for Type 2 allergies and allergen immunotherapy (AIT) has the potential to cater to this approach.
Article content
' Myth busting in peanut allergy: separating fact from fiction ': misconceptions about food allergy management may influence treatment decisions, thus underscoring the vital role of patient-clinician communication.
Article content
' We are enthusiastic to share how Stallergenes Greer is bolstering its impact in the field of respiratory and food allergy. Our research findings highlighted at the symposia, as well as through scientific posters and presentations, reflect our determination to deliver innovative allergen immunotherapy solutions that offer sustained benefits for patients worldwide,'stated Dr Elena Rizova, Chief Medical Officer, Stallergenes Greer. ' Our portfolio offers a broad range of proven treatment solutions designed to provide long-lasting relief for patients with allergies across a spectrum of conditions ranging from allergic rhinitis and asthma to food allergy.'
Article content
The presentation of the posters will showcase Stallergenes Greer's latest research efforts and reaffirm its commitment to advancing personalised allergy care for the benefit of patients and healthcare professionals. Topics include patient benefits with AIT and its potential for clinical remission, new data from the recent real-world study VORAN on 300 IR House Dust Mite (HDM) SLIT tablet, PDAH (defatted powder of Arachis Hypogaea L., semen [peanut]) allergen consistency compared to supermarket peanut products, and prevention of food-induced anaphylaxis in children, including toddlers.
Article content
Chair: Prof. Adnan Custovic, United Kingdom
Article content
POSTERS
Article content
Among the topics covered by the 25 posters, specific findings will be presented and discussed in depth:
Article content
Recent findings highlight the potential of Stallergenes Greer immunotherapies to provide sustained symptom relief and reduce reliance on corticosteroids even after treatment cessation, aligning with the concept of clinical remission on and off treatment. Evidence from VORAN, the first European real-world data generation study with 300 IR HDM SLIT tablet, supports the safety profile and effectiveness of this treatment in HDM-induced allergic rhinitis with or without controlled asthma in more than 700 adults and adolescents, with over 80% having improved their symptoms and sleep and almost 2/3 stopping nasal corticosteroid use. These findings are further supported by the PRACTIS study, where the benefits of SLIT-liquid met expectations in approximately 90% of patients with allergic rhino conjunctivitis and/or asthma.
Article content
Furthermore, Stallergenes Greer recently conducted studies showing that its peanut allergy treatment, PDAH, is consistent and offers a positive risk-benefit ratio. Unlike common peanut products found in supermarkets, which can vary in protein and allergen levels, PDAH shows consistency across batches. The research also points to an opportunity to help children from 1 year, when their immune systems may be more adaptable. In clinical studies, the treatment helped reduce the risk of accidental allergic reactions and showed a solid safety record, especially in toddlers.
Article content
ABOUT THE EAACI CONGRESS
Article content
The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956. EAACI is dedicated to improving the health of people affected by allergic diseases. With more than 16,000 members from 125 countries and over 50 National Allergy Societies, EAACI is the primary source of expertise in Europe and worldwide for all aspects of allergy.
Article content
Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries.
Article content
Article content
Article content
Article content
Contacts
Article content
Stallergenes Greer
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
9 hours ago
- CTV News
Period-tracking apps pose ‘significant risks' for users, new report finds
Experts say companies could sell the data of those who use menstrual cycle tracking apps. (Pexels) Menstrual cycle tracking apps could jeopardize the safety and privacy of users, a new report warns, with personal data commonly sold to companies. The stakes are high since period tracking apps have soared in popularity and become ubiquitous amid limited access to information, a lack of research and stigma about menstruation health. A 2024 study estimates that global downloads for the three most popular menstruation cycle tracking apps surpassed 250 million. Those who use apps that track periods often don't consider the data 'intimate' or commercially valuable, and need more protections from potential abuse of their personal information, according to the report released Tuesday by The Minderoo Centre for Technology and Democracy. MCTD is an independent team of academic researchers at the University of Cambridge in the U.K. 'Menstrual tracking applications turn personal health information into data points to be collected, analyzed, and sold,' according to the report. Data sold to companies, advertisers The study noted the apps pose 'significant risks' for users as femtech has become a 'lucrative trend' and the user data is 'extremely valuable' for a wide range of companies, from those that developed the app to big tech firms and advertising industries. Femtech refers to digital products, services or technologies promoting women's health and wellbeing, with period-tracking apps making up 50 per cent of the US$22 billion market in 2020. 'People vastly underestimate the commercial value of menstrual data and the extent to which it can provide insights into their political preferences, health issues, or reproductive choices,' researchers wrote. The apps offer a way for users to track daily information on anything related to their menstrual health, such as menstrual cycles, predictions on periods, premenstrual syndrome (PMS), ovulation and fertility. Security and privacy risks To add to the concerns, researchers say the apps also pose risks to data security and privacy, noting it's widely used in the online advertising industry. 'Self-tracking data has been used to police people's reproductive choices, to undermine a user's testimony in court, and it can lead to increased vulnerability in intimate relationships, partner violence, risks to job prospects via employer access to CTA (cycle tracking application) data, workplace monitoring, or possible health insurance discrimination,' according to the report. Meanwhile, the report also referred to 'severe security risks,' noting an example in the U.K. where period tracker data was used to charge women for illegally accessing abortion services. Are period apps accurate? The study notes many medical studies showed that the apps 'fail to accurately calculate cycle length or ovulation windows' and additional data from people is often not used to improve predictions. Rather, researchers say the information is 'predominantly a source of value' for the companies. 'With most apps providing no or very little information on how predictions are made, a 2023 study found that some users were encouraged to track more data to fine-tune their predictions and train an imagined algorithm,' it wrote. While users commonly turn to the apps to help them conceive or prevent getting pregnant, people with irregular cycles or conditions such as poly-cystic ovary syndrome, endometriosis, or premenstrual dysphoric disorder may also use the apps to try to understand their medical issues. Many people use the apps to track their emotions and bodily functions as well. Recommendations The report recommends improving health care for and incentivising research on menstrual and reproductive health, such as through cycle tracking companies and research institutes working together. It encourages schools and organizations to help raise awareness about menstrual tracking for all ages. Additionally, it recommends alternatives, such as public bodies developing apps that are 'trustworthy' and collect data in a 'responsible way.' The report also calls for stricter regulation of menstrual tracking data as 'sensitive health information' in the United States and tighter enforcement of existing regulations in the U.K. and European Union. It suggests improving security through 'consent options,' clear and accessible privacy policies, and prioritizing data privacy and security in the app design. Apps could be more 'transparent' by providing clear information on how tracking data is used to make predictions, with interface options for those who cannot or do not want to become pregnant. The report notes that not all women menstruate and not everyone with menstrual cycles is a woman. For instance, it wrote that children and teenagers have periods, trans men can menstruate and trans women can experience symptoms similar to premenstrual syndrome (PMS). Most apps are designed for straight cis women who want to get pregnant, it added. David Young, a privacy and regulatory law expert in Toronto, told in a video interview Monday that Canada's Personal Information Protection and Electronic Documents Act already follows the report's recommendations, though the law is 'not always enforced.' According to Canada's federal privacy law, an organization must not require individuals to consent to the collection, use or disclosure of their information beyond 'explicitly specified, and legitimate purposes.' 'Assuming those specific and legitimate purposes are the tracking that the individual is seeking by use of the app, then they shouldn't be allowed to also require, as a condition of using the app, that they're going to sell that information to somebody else,' Young said. He noted Canada also faces a problem with companies selling consumers' medical data, including electronic health records. Young said menstrual-related cycle data is considered 'sensitive personal health information.' 'And that has a very high standard of compliance under any privacy law, meaning that there must be clear ... consent to for whatever uses are going to be made of that information. So it's not something you can just use by way of implied consent.'
Globe and Mail
20 hours ago
- Globe and Mail
Medtronic announces MiniMed as name for planned New Diabetes Company
GALWAY, Ireland, June 12, 2025 /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company following the intended separation. The name honors the company's roots, reflecting its original name prior to its acquisition by Medtronic in 2001, and a deep 40-year history of being at the forefront of transforming diabetes care around the world.
National Post
a day ago
- National Post
Stallergenes Greer Showcases Developments in Respiratory and Food Allergy Care at EAACI 2025
Article content BAAR, Switzerland — Stallergenes Greer, a global leader in allergy therapeutics, will present insightful scientific developments at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, Glasgow (United Kingdom) June 13-16. Article content The company will present 25 posters and host two scientific symposia during which six world-leading experts will share their insight on respiratory and food allergy: Article content 'Breath of change: redefining respiratory allergy care with remission in sight': with environmental change impacting respiratory allergies, a new approach to disease management is necessary. Clinical remission is emerging as a relevant treatment goal for Type 2 allergies and allergen immunotherapy (AIT) has the potential to cater to this approach. Article content ' Myth busting in peanut allergy: separating fact from fiction ': misconceptions about food allergy management may influence treatment decisions, thus underscoring the vital role of patient-clinician communication. Article content ' We are enthusiastic to share how Stallergenes Greer is bolstering its impact in the field of respiratory and food allergy. Our research findings highlighted at the symposia, as well as through scientific posters and presentations, reflect our determination to deliver innovative allergen immunotherapy solutions that offer sustained benefits for patients worldwide,'stated Dr Elena Rizova, Chief Medical Officer, Stallergenes Greer. ' Our portfolio offers a broad range of proven treatment solutions designed to provide long-lasting relief for patients with allergies across a spectrum of conditions ranging from allergic rhinitis and asthma to food allergy.' Article content The presentation of the posters will showcase Stallergenes Greer's latest research efforts and reaffirm its commitment to advancing personalised allergy care for the benefit of patients and healthcare professionals. Topics include patient benefits with AIT and its potential for clinical remission, new data from the recent real-world study VORAN on 300 IR House Dust Mite (HDM) SLIT tablet, PDAH (defatted powder of Arachis Hypogaea L., semen [peanut]) allergen consistency compared to supermarket peanut products, and prevention of food-induced anaphylaxis in children, including toddlers. Article content Chair: Prof. Adnan Custovic, United Kingdom Article content POSTERS Article content Among the topics covered by the 25 posters, specific findings will be presented and discussed in depth: Article content Recent findings highlight the potential of Stallergenes Greer immunotherapies to provide sustained symptom relief and reduce reliance on corticosteroids even after treatment cessation, aligning with the concept of clinical remission on and off treatment. Evidence from VORAN, the first European real-world data generation study with 300 IR HDM SLIT tablet, supports the safety profile and effectiveness of this treatment in HDM-induced allergic rhinitis with or without controlled asthma in more than 700 adults and adolescents, with over 80% having improved their symptoms and sleep and almost 2/3 stopping nasal corticosteroid use. These findings are further supported by the PRACTIS study, where the benefits of SLIT-liquid met expectations in approximately 90% of patients with allergic rhino conjunctivitis and/or asthma. Article content Furthermore, Stallergenes Greer recently conducted studies showing that its peanut allergy treatment, PDAH, is consistent and offers a positive risk-benefit ratio. Unlike common peanut products found in supermarkets, which can vary in protein and allergen levels, PDAH shows consistency across batches. The research also points to an opportunity to help children from 1 year, when their immune systems may be more adaptable. In clinical studies, the treatment helped reduce the risk of accidental allergic reactions and showed a solid safety record, especially in toddlers. Article content ABOUT THE EAACI CONGRESS Article content The European Academy of Allergy and Clinical Immunology (EAACI) is an association of clinicians, researchers and allied health professionals founded in 1956. EAACI is dedicated to improving the health of people affected by allergic diseases. With more than 16,000 members from 125 countries and over 50 National Allergy Societies, EAACI is the primary source of expertise in Europe and worldwide for all aspects of allergy. Article content Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries. Article content Article content Article content Article content Contacts Article content Stallergenes Greer Article content Article content
